PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Wiltshire Capital

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

The Biotechnology Market to Reach $275M by 2012 Finds Wiltshire Capital - In 2012, the global biotechnology market is forecast to have a value of $275,757 million, an increase of 60.5% over 2007
The Biotechnology Market to Reach $275M by 2012 Finds Wiltshire Capital

 

NewswireToday - /newswire/ - Nishi-Shinjuku, Tokyo, Japan, 2011/05/04 - In 2012, the global biotechnology market is forecast to have a value of $275,757 million, an increase of 60.5% over 2007.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The biotechnology market is an ever-expanding, demanding, and lucrative market. Areas of the biotechnology market include; agriculture GMO, antibody technologies, antisense technology, biomaterials, biopharmaceuticals, drug discovery, emerging technology, environmental/industrial biotechnology, enzymes, gene therapy, general biotechnology, genetic engineering, genomics, informatics, instrumentation and equipment, molecular biology, pharmaceuticals, proteomics, regulation and bioethics, research and development, tissue engineering and wound care.

In 2012, the global biotechnology market is forecast to have a value of $275,757 million, an increase of 60.5% over 2007. In value terms, the medical/healthcare segment generated 69.4% of the global biotechnology market value.

Malaysia has emerged as a major investment destination for biotech companies. The Malaysian biotech market posted high growth last year and is expected to do the same in next few years. Rich biodiversity, availability of low cost human resources and strong government efforts are some of the reasons that have boosted growth in the market. The biotech market in Malaysia is expected to grow around 21% during 2010-2012.

Wiltshire Capital (witshirecapital.com) has studied the Malaysian biotech market by breaking it into three segments – healthcare biotech, agriculture biotech and industrial biotech. Each of these segments has been extensively covered, giving in-depth analysis of the current and future market trends along with valuable data of past trends. The report also provides a complete overview of regulatory environment for the biotech market.

Wiltshire Capital’s report has found that increasing prevalence of diseases and rising exports of drugs from Malaysia are driving growth in the healthcare biotechnology market. This segment holds the highest potential for growth and will post the fastest growth rate among all the three segments.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Wiltshire Capital

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


The Biotechnology Market to Reach $275M by 2012 Finds Wiltshire Capital

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Kaito Hiroshi - WiltshireCapital.com 
+81 345-790199 pr[.]wiltshirecapital.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Wiltshire Capital securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Wiltshire Capital / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)